Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines

Leukemia and Lymphoma

Volumn 53, Issue 11, 2012, Pages 2262-2268

  Castegnaro, Silvia ^a   Visco, Carlo ^a   Chieregato, Katia ^a   Bernardi, Martina ^b   Albiero, Elena ^b   Zanon, Cristina ^a   Madeo, Domenico ^b   Rodeghiero, Francesco ^a,b  

^a SAN BORTOLO HOSPITAL   (Italy)

^b Fondazione Progetto Ematologia   (Italy)

Author keywords

17p CLL; B cell lymphoma; Bendamustine; cytarabine; R BAC; T cell lymphoma

Indexed keywords

BENDAMUSTINE; CYTARABINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LEUKEMIA CELL LINE; LYMPHOMA CELL LINE; MITOCHONDRION; PRIORITY JOURNAL; T CELL LEUKEMIA; T CELL LYMPHOMA;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CYTARABINE; HUMANS; LEUKEMIA; LEUKEMIA, B-CELL; LEUKEMIA, T-CELL; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; NITROGEN MUSTARD COMPOUNDS;

EID: 84867164560     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.688200     Document Type: Article

References (26)

1. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204-210.
2. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is ef ective and has a favorable toxicity prof le in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23:3383-3389.
3. Bergmann MA, Goebeler ME, Herold M, et al. Effcacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005;90:1357-1364. (Pubitemid 41503651)
4. Knop S, Straka C, Haen M, et al. The effcacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90:1287-1288. (Pubitemid 41375295)
5. Ponisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006;132:205-212. (Pubitemid 43144255)
6. von Minckwitz G, Chernozemsky I, Sirakova L, et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-f uorouracil (BMF) versus cyclophosphamide, methotrexate and 5-f uorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 2005;16:871-877. (Pubitemid 41215753)
7. Schmittel A, Knodler M, Hortig P, et al. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 2007;55:109-113. (Pubitemid 46043579)
8. Koster W, Heider A, Niederle N, et al. Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer. J Torac Oncol 2007;2:312-316. (Pubitemid 47181714)
9. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14:309-317. (Pubitemid 351378007)
10. Strumberg D, Harstrick A, Doll K, et al. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996;7:415-421. (Pubitemid 26249195)
11. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol 2002;128:603-609. (Pubitemid 35435557)
12. Leoni LM, Niemeyer CC, Kerfoot C, et al. In vitro and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells. Proc Am Assoc Cancer Res 2004;45: Abstract 1215.
13. Chou TC, Arlin Z, Clarkson BD, et al. Metabolism of 1-beta-D- arabinofuranosylcytosine in human leukemic cells. Cancer Res 1977;37:3561-3570. (Pubitemid 8198413)
14. Kessel D, Hall TC, Wodinsky I. Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside. Science 1967;156:1240-1241.
15. Kufe DW, Major PP, Egan EM, et al. Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem 1980;255:8997-8900.
16. Spriggs D, Robbins G, Ohno Y, et al. Detection of 1-beta-D- arabinofuranosylcytosine incorporation into DNA in vivo. Cancer Res 1987;47:6532-6536. (Pubitemid 18019650)
17. Peters WG, Colly LP, Willemze R. High-dose cytosine arabinoside: pharmacological and clinical aspects. Blut 1988;56:1-11. (Pubitemid 18039726)
18. Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993;11:116-124. (Pubitemid 23059984)
19. Staib P, Schinkothe T, Dimsky T, et al. In vitro modulation of Ara-ctp accumulation in fresh AML cells by bendamustine in comparison with f udarabine, 2-CdA and gemcitabine. Blood 1999;94(Suppl. 1): Abstract 271.
20. Chow KU, Boehrer S, Napieralski S, et al. In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential. Leuk Lymphoma 2003;44:165-173. (Pubitemid 36113846)
21. Visco C, Castegnaro S, Chieregato K, et al. The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells Mol Dis 2012;48:68-75.
22. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473-4479.
23. Schwänen C, Hecker T, Hubinger G, et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 2002;16:2096-2105. (Pubitemid 35203454)
24. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29:3559-3566.
25. Gandhi V. Metabolism and mechanisms of action of benda-mustine: rationales for combination therapies. Semin Oncol 2002; 29(Suppl. 13):4-11. (Pubitemid 34857890)
26. Visco C, Lissandrini L, Zambello R, et al. Rituximab, benda-mustine and cytarabine (R-BAC) is a very active regimen in patients with mantle cell lymphoma not eligible for intensive chemotherapy or autologous transplant. Ann Oncol 2011;22(Suppl. 4): Abstract 236.